Swedencare (STO: SECARE) Shares Plunge 17% After Q2 Revenue Misses Analyst Estimates

Swedencare shares plunged 17% Wednesday after second-quarter results missed Wall Street expectations. The pet health company reported net sales of SEK 670 million for Q2 2026. That figure grew just 4% year-over-year but missed consensus estimates by 4%. Operational EBITDA reached SEK 129 million, also up 4%, yet fell 5% short of forecasts. 

North America drove the shortfall, with organic growth declining 3% there. Europe and Production both posted strong growth, up 19% and 25% respectively. Management said underlying demand remains healthy despite the disappointing headline numbers.

Swedencare’s Q2 2026 Results in Detail

Swedencare posted net sales of SEK 670 million for the quarter. That represented 4% year-over-year growth but landed 4% below analyst consensus. Operational EBITDA came in at SEK 129 million, up 5% year-over-year. That figure still missed expectations by 5%, with margin at 19.3%.

Swedencare’s key Q2 2026 financial figures:

• Net sales reached SEK 670 million, up 4% year-over-year.
• Operational EBITDA hit SEK 129 million, missing estimates by 5%.
• Operational EBIT fell 2% year-over-year to SEK 103 million.
• EBIT margin slipped to 15.4%, down from 16.3% a year earlier.

Why North America Dragged Down Swedencare’s Growth

North America organic growth declined 3% during the second quarter. A delayed delivery to a major new FDMC customer caused part of the shortfall. Veterinary distributors also made temporary inventory reductions during the period. Swedencare said the delayed shipment has since been approved for delivery.

Swedencare’s Stock Reaction to the Miss

Swedencare shares fell 17% following Wednesday’s results release. Investors reacted sharply to both the revenue and profitability shortfalls. Rising Amazon-related costs and marketing spending compressed margins further this quarter. Those investments targeted Prime Day promotions and NaturVet’s e-commerce expansion specifically.

What pressured Swedencare’s margins this quarter:

• Higher Amazon-related selling costs weighed on overall profitability.
• Marketing spend increased around Prime Day promotional events.
• New product launches added incremental costs during the quarter.
• European e-commerce expansion required additional upfront investment.

Swedencare’s Segment Performance Was Mixed

Dental products delivered Swedencare’s strongest segment performance this quarter. Dental revenue reached SEK 157 million, up 41% year-over-year and 44% organically. Nutraceuticals revenue fell 5% to SEK 276 million, still Swedencare’s largest segment overall. Topicals and Dermatology declined 11% to SEK 125 million during the same period.

$GEV shares are now lower after Q2 EPS missed expectations, even as the broader print showed strong demand and cash generation

The main weak spot remains Wind, where revenue fell 10% & segment EBITDA loss widened to $275M on lower Onshore volume and higher Offshore project costs https://t.co/muUETOuHQZ pic.twitter.com/89XGZrAn4d

— Wall St Engine (@wallstengine) July 22, 2026

Bright Spots Beneath Swedencare’s Headline Miss

Pharma revenue grew 27% year-over-year to SEK 58 million this quarter. That segment also posted 33% organic growth, its strongest rate company-wide. Europe delivered 19% organic growth, offsetting North America’s weakness substantially. Production grew organically by 25%, supporting Swedencare’s manufacturing base further.

Products showing resilience despite the broader miss:

• ProDen PlaqueOff grew 31% organically during the second quarter.
• Dental’s 44% organic growth led all of Swedencare’s segments.
• Pharma’s 33% organic growth also outpaced company-wide averages.
• Management called underlying demand across markets genuinely healthy.

Swedencare’s Path Forward After the Delayed Shipment

Swedencare’s delayed FDMC shipment has now received customer approval. Management expects that delivery will support stronger performance in the second half. The company’s leadership, CEO Håkan Lagerberg and CFO Jenny Graflind, presented these results Wednesday. Investors will watch whether North America rebounds as guided over coming quarters.

Final Thoughts

Swedencare’s 17% share price drop reflects genuine disappointment with this quarter’s headline miss. Both revenue and operational EBITDA fell short of what analysts had modeled. Still, Dental’s 44% organic growth and Europe’s 19% expansion show real underlying strength. North America’s delayed shipment issue appears temporary rather than structural in nature. The second half of 2026 will show whether Swedencare’s growth story stays intact.

Disclaimer:

The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.